ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Celgene Corporation

Celgene Corporation (CELG)

108.24
0.00
(0.00%)
Closed 07 December 8:00AM
108.24
0.00
( 0.00% )
Pre Market: 11:00AM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
108.24
Bid
109.30
Offer
109.37
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
108.24
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

CELG Latest News

NexImmune Appoints Sol Barer as Chairman of the Board of Directors

GAITHERSBURG, Md., Dec. 16, 2019 (GLOBE NEWSWIRE) -- NexImmune, a clinical-stage biopharmaceutical company developing novel immune-therapeutics based on a proprietary Artificial Immune...

Amgen Completes Acquisition Of Otezla® (apremilast)

Amgen Completes Acquisition Of Otezla® (apremilast) Differentiated Therapy Strengthens Amgen's Long-Standing Expertise in Inflammation PR Newswire THOUSAND OAKS, Calif., Nov. 21, 2019 THOUSAND...

Celgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristo...

Celgene Corporation (NASDAQ: CELG) announced today that following the completion of Celgene’s acquisition by Bristol-Myers Squibb Company (NYSE: BMY), Bristol-Myers Squibb and Celgene plan to...

CELGENE ERHÄLT DIE ZULASSUNGSEMPFEHLUNG DES CHMP FÜR LENALIDOMID (REVLIMID®) IN KOMBINATION MIT RITUXIMAB ZUR BEHANDLUNG V...

Die Kombination aus Lenalidomid (REVLIMID®) und Rituximab (R2) hat das Potenzial, eine chemotherapiefreie Behandlungsoption für rezidivierte oder refraktäre Patienten mit follikulärem Lymphom zu...

Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500

Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500 PR Newswire NEW YORK, Nov. 19, 2019 NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc...

Exelon Corporation to Join the NASDAQ-100 Index Beginning November 21, 2019

NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Exelon Corporation (Nasdaq: EXC), will become a component of the NASDAQ-100 Index® (Nasdaq: NDX), the...

FTC Requires Bristol-Meyers Squibb, Celgene to Divest Otezla as Condition of Acquisition

By Stephen Nakrosis The U.S. Federal Trade Commission said Friday Celgene Corp. (CELG) agreed to divest its Otezla psoriasis treatment as a condition of the company's planned acquisition by...

Celgene Gets CHMP Positive Opinion for Revlimid/Rituximab Combo in Follicular Lymphoma

By Colin Kellaher Celgene Corp. (CELG) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Revlimid in combination with...

Celgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult...

REVLIMID® and rituximab (R2) has the potential to become a chemotherapy-free combination treatment option for patients with follicular lymphoma who have relapsed or did not respond to previous...

Skyhawk Therapeutics annonce une deuxième entente de collaboration multicible avec Celgene pour découvrir et mettre au poin...

Skyhawk Therapeutics annonce une deuxième entente de collaboration multicible avec Celgene pour découvrir et mettre au point de petites molécules novatrices qui modulent...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
ZEOZeo Energy Corporation
US$ 2.82
(115.27%)
15.79M
MSPRMSP Recovery Inc
 2.60
(62.50%)
12.53k
MRMMEDIROM Healthcare Technologies Inc
US$ 4.65
(52.46%)
2.13M
GXAIGaxos ai Inc
US$ 3.96
(52.31%)
7.73M
DUOFangDD Network Group Ltd
US$ 0.8072
(39.61%)
17.34M
BIOABioAge Labs Inc
US$ 6.04
(-69.94%)
76.87k
UPCUniverse Pharmaceuticals Inc
US$ 2.35
(-30.68%)
255.8k
GVHGlobavend Holdings Ltd
US$ 0.55
(-19.14%)
60
VMDVieMed Healthcare Inc
US$ 7.00
(-18.79%)
101
FORRForrester Research Inc
US$ 14.01
(-17.35%)
1
RIMEAlgorhythm Holdings Inc
US$ 0.126
(36.96%)
55.73M
RGTIRigetti Computing Inc
US$ 4.96
(13.24%)
22.32M
DUOFangDD Network Group Ltd
US$ 0.8074
(39.64%)
17.34M
SXTCChina SXT Pharmaceuticals Inc
US$ 0.4555
(23.11%)
16.96M
ZEOZeo Energy Corporation
US$ 2.81
(114.50%)
15.79M

CELG Discussion

View Posts
BottomBounce BottomBounce 4 years ago
Better Buy: Celgene vs. Gilead Sciences
Which stock wins in a battle between these two big biotechs?

https://fool.com/investing/2019/09/14/better-buy-celgene-vs-gilead-sciences.aspx $CELG $GILD
👍️0
patrickjishere patrickjishere 6 years ago
Sorry, don’t know
👍️0
rosemountbomber rosemountbomber 6 years ago
Do you or anyone here know the tax treatment of the CVR??
👍️0
TheFinalCD TheFinalCD 6 years ago
Advances in Cancer Drugs Fuel Deal -- WSJ
https://ih.advfn.com/stock-market/NASDAQ/celgene-CELG/stock-news/78990612/advances-in-cancer-drugs-fuel-deal-wsj
👍️0
patrickjishere patrickjishere 6 years ago
Yep, I like BMY and the deal. Very fair to put a $9 a share bonus for the 3 NDA's they have been working on.
👍️0
Johnny_C Johnny_C 6 years ago
Good call, a good analyst always starts with a low upside and then can move up. Are you moving up. RCPT killed CELG, I was lucky CELG bought it I guess as it was a 300% winner for us.

This could be a very good fit with BMY
👍️0
patrickjishere patrickjishere 6 years ago
I thought I was a genius when I bought these guys at 88. I'm stunned at how poorly they have been managed. Interested in your insights going forward. Thanks for the comments.
👍️0
biotech_researcher biotech_researcher 6 years ago
I don’t know. But, there was some dialog on Twitter over the last several days about some issue with one of their trials. They have made some bonehead moves over the last few years.
👍️0
patrickjishere patrickjishere 6 years ago
Now is the time to buy for a trade 63 to 71...thoughts?
👍️0
biotech_researcher biotech_researcher 6 years ago
$50’s for Celgene?
👍️0
StockLearner2011 StockLearner2011 6 years ago
https://www.mdmag.com/medical-news/ashish-khanna-md-checking-in-on-angiotensin-2
👍️0
biotech_researcher biotech_researcher 6 years ago
Something is wrong with Celgene, and it is not just the general decline in the market....
👍️0
ITMS ITMS 6 years ago
Celgene Corp $CELG Chart Signals Trouble

Shares of Celgene Corp (CELG) have a nasty chart and pro traders are alerting investors. The stock price is currently forming a classic bear flag pattern. To make matters worse, the daily 20, 50 and 200 moving averages are just above current price and turning lower. This signals a likely fall on Celgene Corp in the coming weeks to as low as $75.00.




Gareth Soloway
InTheMoneyStocks
👍️0
biotech_researcher biotech_researcher 6 years ago
As the old saying goes, there is usually more than one rotten apple in the box after you find the first one. Does Mark have another?
👍️0
BottomBounce BottomBounce 6 years ago
7 Companies We'd Buy and Hold for the Next 20 Years $KNDI $DIS $CELG $NPD $AGN $PFE $TSLA
https://www.fool.com/investing/general/2016/03/12/7-companies-wed-buy-and-hold-for-the-next-20-years.aspx
👍️0
ITMS ITMS 6 years ago
Breakout Alert: Celgene $CELG

Shares of Celgene Corp (CELG) are beginning to breakout on the daily stock chart. This pattern setup is fantastic as money is beginning to flow from over-bought sectors to under-bought sectors. In a market priced to perfection, the biotechnology stocks have drastically lagged. Their valuations are extremely attractive compared to an Amazon (AMZN) and Netflix (NFLX). The Celgene stock chart has formed a beautiful bull flag just off the 52 week lows. Today, the breakout is beginning as the stock is up over 2% and cracking the upper band trend line. Look for an upside target of $86 in the near-term.





Gareth Soloway
InTheMoneyStocks
👍️0
biotech_researcher biotech_researcher 7 years ago
They need to fire Mark Alles, CEO, to stop the bleeding..
👍️0
biotech_researcher biotech_researcher 7 years ago
Now I know why they call it the Motley Fool...
👍️0
biotech_researcher biotech_researcher 7 years ago
Surprised that the CEO of Celgene, Mark Alles, is still heading the firm. Commentary from other individuals indicate he is in over his head, and I tend to agree.. should be removed. The board should be a target as the have abandoned their fiduciary responsibility by adding all the additional titles to Alles.
👍️0
Pennies_Envy Pennies_Envy 7 years ago
CELG falling knife damn
👍️0
joanne4trade joanne4trade 7 years ago
CELG remains volatile because of several product issues as well as approaches to biotech. CELG leading indicators highlighted the downward trend in November 2017, and has remained in a negative zone, despite the temporary rebounds.

https://www.blusignalsystems.com/behind-downward-cycle-celg-stock-what-leading-indicators-knew/
👍️0
biotech_researcher biotech_researcher 7 years ago
CELG has made mistake after mistake..
👍️0
MinnieM MinnieM 7 years ago
$CELG - Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases

https://www.nasdaq.com/press-release/prothena-announces-global-neuroscience-research--development-collaboration-with-celgene-for-novel-20180320-01160




👍️0
ITMS ITMS 7 years ago
Celgene Corp $CELG Is Trending Down, Know This Level

Leading biotechnology stock Celgene Corp (NASDAQ:CELG) has been trending lower since October 2017. At that time, the stock traded as high as $147.17 a share. Today, CELG stock is trading around the $87.00 area. Traders can easily see how this stock has fallen from grace over the past five months. The stock is now trading below its 50 and 200 week moving averages, this is a very negative chart formation. The stock should now find some solid support around the $82.75 area. This is a major retrace level where the stock could bounce from the current oversold condition.




Nicholas Santiago
InTheMoneyStocks
👍️0
biotech_researcher biotech_researcher 7 years ago
biotech 2050 (@Biotech2050)
3/12/18, 7:58 AM
@tgtxdough $CELG #REVLIMID has just been approved in China and sold by $BGNE
👍️0
BottomBounce BottomBounce 7 years ago
$CELG 7 Companies We'd Buy and Hold for the Next 20 Years
https://www.fool.com/investing/general/2016/03/12/7-companies-wed-buy-and-hold-for-the-next-20-years.aspx
👍️0
biotech_researcher biotech_researcher 7 years ago
Three huge screw ups recently. That huge swishing sound you hear are the institutional holders dumping their shares. Time to enter..
👍️0
biotech_researcher biotech_researcher 7 years ago
Rallying back hard...
👍️0
shub shub 7 years ago
Looks like we've stopped falling, maybe.
I'm getting in on this dip...
Even with the recent drop i'm nicely ahead on CELG.
👍️0
dannyzee84 dannyzee84 7 years ago
Sold at limit sell 1.25
👍️0
PennyStocksGuru PennyStocksGuru 7 years ago
5 year low is around $50. Just dipped below 3 year low. Ouch!
👍️0
PennyStocksGuru PennyStocksGuru 7 years ago
It was a great short at $140.
👍️0
shub shub 7 years ago
It seems to me that the selloff is considerably overblown.
CELG still has an impressive pipeline, cash and a talent for picking up new drugs very profitably.
As this drop illustrates, there is a substantial failure rate in clinical trials, but the market gasps and clutches it's proverbial breast in surprise each time.
Seems to me to be a very clear BUY signal, and i will as soon as it stops sinking!
👍️0
Jld3294 Jld3294 7 years ago
Well there goes two years of solid gains. :(
👍️0
dannyzee84 dannyzee84 7 years ago
In some 95p .9 short leash
👍️0
Inoviorulez Inoviorulez 7 years ago
https://seekingalpha.com/article/4115337-celgene-dumps-chrons-disease-fight-yet
👍️0
NorFoster NorFoster 7 years ago
Financial impact of stopping Crohn's disease trials. Many people will not know the financial impact. Celgene has announced that info in an SEC filing. alphastreet.com/bce290d5
👍️0
plexrec plexrec 7 years ago
Celgene longs--be smart--move your biotech $$$$$$ to Anavex (Avxl)---fantastic future with CNS drugs---Alzheimer's--Parkinsons---Rett Syndrome---depression etc----huge winner here !!!!!! 3 clinical trials stating this year---huge possibility for success !!!!
👍️0
north40000 north40000 7 years ago
Noticed AH drop in share price, thank you. We hold no CELG except as it may be in portfolios of LABU or FBIOX...likely in both.
👍️0
MinnieM MinnieM 7 years ago
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
http://ir.celgene.com/releasedetail.cfm?ReleaseID=1044647

👍️0
north40000 north40000 7 years ago
CELG: looks like no link available from IBD Weekly 'til Monday.
👍️0
north40000 north40000 7 years ago
IBD names CELG as #1 in a new feature---its Innovator Awards 2017---for "groundbreaking treatments recently introduced to the market or well along in the new-product pipeline."

BIIB, REGN, INCY, KITE and LOXO are also named. I will post a link later---the text occupies several pages.
👍️0
shub shub 7 years ago
Thanks Georgejjl;
Both Folkman's name and D'Amato's appear across a surprisingly diverse range of fields. Literally awesome people!
Our culture is so stupidly stuck in a positive-negative, win-fail mind set that we learn less and less from our mistakes..
A self handicapping mindset.
Most every novel screw up. is a potential technique in another context....If we can learn from them.
👍️0
georgejjl georgejjl 7 years ago
I agree 100%

A big thank needs to go out to The late great Dr. Moses Judah Folkman and Dr. Robert D'Amato for their hypothesis that thalidomide has anti-angiogenesis properties that allow it to cut off the blood supply to cancerous tumors.

Good luck and GOD bless,

George
👍️0
shub shub 7 years ago
It's true..Out of that disastrous drug error, CELG has changed the problematic chemistry and saved or benefitted millions of sick folks.
They've also done very nicely for my stock portfolio.

Every mistake is a learning opportunity.
Some of our most important medicines were discovered thus.
👍️0
Inoviorulez Inoviorulez 7 years ago
https://seekingalpha.com/article/4095766-celgene-paves-way-rare-aml-patients
👍️0
ITMS ITMS 8 years ago
This Leading Biotechnology Level Should Be On The Radar

One of the leading biotechnology stocks in the world is Celgene Corporation (NASDAQ:CELG). This company discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases. Celgene stock topped out on March 17th at $127.64 a share. Today, Celgene stock is trading at $116.97 a share. Traders can easily see that this leading biotechnology stock has been trending lower on the charts lately. The stock now has major chart support around the $110.00 level. This is an area where the major institutional money supported the equity back in December 2016. Often, old pivot levels will serve as major chart support when retested.



Nicholas Santiago
InTheMoneyStocks
👍️0
MinnieM MinnieM 8 years ago
$CELG - How AbbVie's 2020 Strategy Parallels Celgene's
https://seekingalpha.com/article/4067980-abbvies-2020-strategy-parallels-celgenes




👍️0
georgejjl georgejjl 8 years ago
Celgene: Otezla (Apremilast), Revlimid (Lenalidomide), Pomalyst in the U.S.[3] and Imnovid in EU and Russia (Pomalidomide) are all derived from the notorious sedative thalidomide. Celgene has built a multibillion dollar business based on thalidomide and its derivatives.

https://en.wikipedia.org/wiki/Development_of_analogs_of_thalidomide

http://www.newsweek.com/nazis-and-thalidomide-worst-drug-scandal-all-time-64655

GOD bless,

George
👍️0
ValueInvestor15 ValueInvestor15 8 years ago
Cowen and Co reiterated Celgene at Outperform. Valuation models show nice Upside:

Upside Analysis
👍️0

Your Recent History

Delayed Upgrade Clock